David Sheridan
A5084947428- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Liver Disease and Transplantation
- Systemic Lupus Erythematosus Research
- Liver Diseases and Immunity
- Hepatitis B Virus Studies
- Alcohol Consumption and Health Effects
- Diet, Metabolism, and Disease
- Atherosclerosis and Cardiovascular Diseases
- Drug Transport and Resistance Mechanisms
- Pediatric Hepatobiliary Diseases and Treatments
- Immune Cell Function and Interaction
- Systemic Sclerosis and Related Diseases
- Metabolomics and Mass Spectrometry Studies
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Organ Transplantation Techniques and Outcomes
- Palliative Care and End-of-Life Issues
- Cardiac electrophysiology and arrhythmias
- Long-Term Effects of COVID-19
- Nutrition and Health in Aging
- Hormonal Regulation and Hypertension
- Peroxisome Proliferator-Activated Receptors
- Diabetes and associated disorders
- interferon and immune responses
University of Plymouth
2015-2024
University Hospitals Plymouth NHS Trust
2017-2023
Demos
2023
National Health Service
2022
Derriford Hospital
2019
Catalina Research Institute
2018
Novo Nordisk (Switzerland)
2018
Second Genome (United States)
2018
Glympse Bio
2018
Plymouth Hospital
2017
The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority to identify patients with steatohepatitis (NASH) who are at greater risk progression cirrhosis, will be candidates for clinical trials emerging new pharmacotherapies. We aimed develop score NASH, elevated NAFLD activity (NAS≥4), advanced fibrosis (stage 2 or higher [F≥2]).This prospective study included derivation cohort before validation in multiple international cohorts. was...
Vijayaprakash Suppiah and colleagues show that genotyping hepatitis C patients for the IL28B, HLA-C, KIR genes improves ability to predict whether or not will respond antiviral treatment.
Abstract Tissue fibrosis is a core pathologic process that contributes to mortality in ~45% of the population and likely be influenced by host genetic architecture. Here we demonstrate, using liver disease as model, single-nucleotide polymorphism ( rs12979860) intronic region interferon-λ4 (IFNL4) strong predictor an aetiology-independent manner. In cohort 4,172 patients, including 3,129 with chronic hepatitis C (CHC), 555 B (CHB) 488 non-alcoholic fatty (NAFLD), those rs12979860CC have...
Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, polymorphism in the MBOAT7 locus, as being associated with development alcoholic cirrhosis. Here we explore role this variant on inflammation and fibrosis two cohorts patients chronic hepatitis C. In 2,051 patients, rs641738 severe hepatic increased risk fibrosis, well fast progression. At functional level, transcript protein levels blood, serum...
A genome‐wide exome association study has identified the transmembrane 6 superfamily member 2 ( TM6SF2 ) rs58542926 variant encoding an E167K substitution as a genetic determinant of hepatic steatosis in nonalcoholic fatty liver disease (NAFLD). The roles this across spectrum diseases and pathologies on serum lipids comparing viral hepatitis to NAFLD load chronic hepatitis, well its intrahepatic molecular signature, have not been characterized. We undertook detailed analyses 3260 subjects...
Summary Background Palliative care remains suboptimal in end‐stage liver disease. Aim To inform a definitive study, we assessed palliative long‐term abdominal drains disease to determine recruitment, attrition, safety/potential effectiveness, questionnaires/interview uptake/completion and make preliminary cost comparison. Methods A 12‐week feasibility nonblinded randomised controlled trial comparing large‐volume paracentesis vs refractory ascites due with fortnightly home visits for...
Summary Background Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory anti‐pruritic effects. Aims To evaluate the long‐term safety efficacy of seladelpar patients with PBC. Methods In an open‐label, international, extension study, PBC completing lead‐in studies continued treatment. was taken orally once daily at doses 5 or 10 mg...
Unlike for advanced liver fibrosis, the practical rules early non-invasive diagnosis of cirrhosis in NAFLD remain not well defined. Here, we report derivation and validation a stepwise diagnostic algorithm 1568 patients with biopsy coming from four independent cohorts. The study algorithm, using first elastography-based tests Agile3+ Agile4 then specialized blood FibroMeterV3G CirrhoMeterV3G, provides stratification groups, last which is enriched (71% prevalence set). A risk prediction chart...
Background Chronic HCV (CHC) infection is associated with autoimmunity. IgG autoantibodies to apolipoprotein A-I (AAA-I) predict all-cause mortality. We evaluated AAA-I in CHC patients and those who were not viraemic, either because of spontaneous resolution (SR) or clearance following sustained virological response (SVR) after interferon therapy. limited the study genotypes 1 3, dominant circulating UK. Methods Serum samples from 126 114 nonviraemic individuals (25 SR 89 SVR) assayed for...
Hepatitis C virus (HCV) co-opts very-low-density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB-100 variable amounts of apolipoproteins E C, cholesterol triglycerides.To determine whether baseline lipid levels predicted treatment outcome.Retrospective analysis was performed 250 chronic hepatitis (CHC) patients who had received anti-viral agents interferon-alpha ribavirin; 165 a...